Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonis Valachis

Showing results (21-30 of 91) with videos related to

Pageof 10
Sort By:
Targeted Oncology|August 1, 2022
Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysisEvangelos Digkas, Anthony Jagri Tabiim, Daniel Smith, et al.
Acta Oncologica (Stockholm, Sweden)|March 6, 2025
Metastatic triple-negative breast cancer - current treatment strategies in the Nordics: a modified Delphi studyAntonis Valachis, Peeter Karihtala, Jürgen Geisler, et al.
British Journal of Cancer|April 29, 2026
Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?Antonis Valachis, Jürgen Geisler, Peeter Karihtala, et al.
Breast (Edinburgh, Scotland)|May 17, 2024
Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based studyServah Hosseini-Mellner, Åsa Wickberg, Andreas Karakatsanis, et al.
International Journal of Cancer|May 1, 2013
Cardiac toxicity in breast cancer patients treated with dual HER2 blockadeAntonis Valachis, Andreas Nearchou, Nikolaos P Polyzos, et al.
Acta Oncologica (Stockholm, Sweden)|September 15, 2023
Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi studyJürgen Geisler, Peeter Karihtala, Malgorzata Tuxen, et al.
Clinical Breast Cancer|January 7, 2024
Intraoperative Radiation Therapy Delivered by Brachytherapy in Breast Cancer: An Interim Analysis of a Phase 2 TrialÅsa Wickberg, Clara Prag, Antonis Valachis, et al.
JAMA Network Open|December 1, 2022
Yield of Surveillance Imaging After Mastectomy With or Without Reconstruction for Patients With Prior Breast Cancer: A Systematic Review and Meta-analysisDaniel Smith, Setara Sepehr, Andreas Karakatsanis, et al.
Clinical Genitourinary Cancer|December 3, 2014
Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-AnalysisAndreas Nearchou, Antonis Valachis, Pehr Lind, et al.
Gynecologic Oncology|January 12, 2010
Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysisAntonis Valachis, Nikolaos P Polyzos, Vassilis Georgoulias, et al.
Pageof 10

Showing results (21-30 of 91) with videos related to

Sort By:
Pageof 10
Targeted Oncology|August 1, 2022
Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysisEvangelos Digkas, Anthony Jagri Tabiim, Daniel Smith, et al.
Acta Oncologica (Stockholm, Sweden)|March 6, 2025
Metastatic triple-negative breast cancer - current treatment strategies in the Nordics: a modified Delphi studyAntonis Valachis, Peeter Karihtala, Jürgen Geisler, et al.
British Journal of Cancer|April 29, 2026
Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence?Antonis Valachis, Jürgen Geisler, Peeter Karihtala, et al.
Breast (Edinburgh, Scotland)|May 17, 2024
Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based studyServah Hosseini-Mellner, Åsa Wickberg, Andreas Karakatsanis, et al.
International Journal of Cancer|May 1, 2013
Cardiac toxicity in breast cancer patients treated with dual HER2 blockadeAntonis Valachis, Andreas Nearchou, Nikolaos P Polyzos, et al.
Acta Oncologica (Stockholm, Sweden)|September 15, 2023
Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi studyJürgen Geisler, Peeter Karihtala, Malgorzata Tuxen, et al.
Clinical Breast Cancer|January 7, 2024
Intraoperative Radiation Therapy Delivered by Brachytherapy in Breast Cancer: An Interim Analysis of a Phase 2 TrialÅsa Wickberg, Clara Prag, Antonis Valachis, et al.
JAMA Network Open|December 1, 2022
Yield of Surveillance Imaging After Mastectomy With or Without Reconstruction for Patients With Prior Breast Cancer: A Systematic Review and Meta-analysisDaniel Smith, Setara Sepehr, Andreas Karakatsanis, et al.
Clinical Genitourinary Cancer|December 3, 2014
Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-AnalysisAndreas Nearchou, Antonis Valachis, Pehr Lind, et al.
Gynecologic Oncology|January 12, 2010
Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysisAntonis Valachis, Nikolaos P Polyzos, Vassilis Georgoulias, et al.
Pageof 10